Nicholas Florko on Muck Rack

Nicholas Florko

Washington, DC
Managing Editor — Inside Health Policy
As seen in: Inside Health Policy
Covers:  FDA policy, drug pricing, pharmaceutical promotion, congressional actions on health (particularly actions of Energy & Commerce and Senate HELP), U.S. Supreme Court and lower court health law cases.
Doesn't Cover: Medicare and Medicaid, or the anything dealing with private health insurance. Premarket drug development, or anything dealing with shareholders / individual companies.

Managing Editor @InHealthPolicy's FDA Week. Covering all things FDA policy (and occasionally politics) I have a soft spot for drug pricing, IP and litigation.

Search Tweets

Twitter Feed

@NicholasFlorko — 545 followers, 1,870 tweets

@SarahKarlin @chesterdavisjr totally get it! We are cheap (comparatively)! Y’all need a subscription, ha.
@SarahKarlin @chesterdavisjr I generally would agree. But like I said to Chip, I think it's important we point out who is lobbying FDA regardless of funding and when arguments don't bear out, point that out -- which is what I attempted to do in parts of this story.
@chesterdavisjr Frankly, I'm less of an expert in that arena and I won't write something unless I'm confident in my reporting. Much less of a follow-the-money guy and much more of a policy wonk. My own weakness I need to work on!
@chesterdavisjr Also, I know my past comment doesn't address what you're getting at, but I included their members in the story so folks who want to explore that arena can. That wasn't the focus of the story, but I agree it's an important avenue to explore.
@chesterdavisjr I think my reporting on their comments was a very balanced take -- namely I pointed out that EMA and FDA say their arguments about safety don't bear out. Important nonetheless to point out who is lobbing FDA, IMO.
Show More